CORT - Corcept Therapeutics Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
268,362
251,247
159,201
81,321
50,286
Cost of Revenue
5,504
5,215
3,554
2,058
1,361
Gross Profit
262,858
246,032
155,647
79,263
48,925
Operating Expenses
Research Development
79,554
75,247
40,376
23,844
15,419
Selling General and Administrative
91,848
81,289
62,416
45,240
36,949
Total Operating Expenses
171,402
156,536
102,792
69,084
52,368
Operating Income or Loss
91,456
89,496
52,855
10,179
-3,443
Interest Expense
-
-
49
2,039
2,965
Total Other Income/Expenses Net
-
-
-
0
0
Income Before Tax
95,532
92,153
52,806
8,140
-6,408
Income Tax Expense
17,317
16,743
-76,316
-
-
Income from Continuing Operations
78,215
75,410
129,122
8,140
-6,408
Net Income
78,215
75,410
129,122
8,140
-6,408
Net Income available to common shareholders
78,215
75,410
129,122
8,140
-6,408
Reported EPS
Basic
-
0.65
1.14
0.07
-0.06
Diluted
-
0.60
1.04
0.07
-0.06
Weighted average shares outstanding
Basic
-
115,343
113,527
110,566
106,883
Diluted
-
126,688
124,515
116,139
106,883
EBITDA
-
89,496
52,855
10,266
-3,288